DexCom (DXCM) Tops Q2 EPS by 44c, Revenues Beat; Offers FY20 Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
DexCom (DXCM) PT Raised to $540 at Cowen
July 24, 2020 8:07 AM EDTCowen analyst Doug Schenkel raised the price target on DexCom (NASDAQ: DXCM) to $540.00 (from $450.00) while maintaining an Outperform rating.
The analyst commented, "UnitedHealthcare recently announced the launch of its Level2 program for Type 2 diabetes management. All participants are required to wear a DXCM... More
